Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco D’amore ,Georg Hopfinger,Christian Steidl,Javeed Iqbal,Peter De Nully Brown,Jan Walewski,Michel Van Gelder,Milada Jankovská,Christian Gisselbrecht,Unn Merete Fagerli,Arjan Diepstra,Rob Fijnheer,Ka Lung Wu,Sirpa Leppä,Randy D Gascoyne,Alyssa Bouska,Bettina Altmann,Esa Jantunen,Andreas Rosenwald,Eckhart Weidmann,Peter Noergaard,Ilse Christiansen,Thomas Relander,Thomas Noesslinger,Marita Ziepert,David W Scott,Laurence De Leval,Helle Toldbod,Gerald Wulf,Christer Sundström,Antonio Pezzutto,Hans Hagberg,Lorenz Truemper,Grzegorz Rymkiewicz,Jeanette K Doorduijn,Markus Loeffler,Maria Gomes Da Silva,Andreas Chott,Wing C Chan ,Ludmila Boudová ,Jacob Haaber Christensen ,Hanneke C Kluin‐Nelemans ,Hilde Demuynck ,José Mário Mariz ,V I T Prochazka ,Pieternella J Lugtenburg ,Pär Josefsson ,Josée M Zijlstra ,Lauren C Chong ,A Van Hoof ,Grete F Lauritzsen ,Jan Delabie ,Marja‐Liisa Karjalainen‐Lindsberg ,Mats Merup ,José Cabeçadas ,Knut Liestøl ,Lynette M Smith ,Éric Van Den Neste

doi:10.1182/blood-2018-99-110429

Abstract

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Full Text